文献速递心脏核医学

18F-Flutemetamol动态参数PET评估他法米迪治疗ATTR心脏淀粉样变

Parametric Cardiac Imaging with 18F-Flutemetamol PET to Evaluate the Impact of Tafamidis in Patients with Transthyretin Cardiac Amyloidosis.
PubMed 文献 · J Nucl Med · 2026-05-01

结果显示,经代谢物及血浆校正输入函数的2组织可逆模型拟合最佳,采用2–20分钟数据的多线性分析1法生成的分布容积(VT)图像方差最低,VT在他法米迪治疗6个月后显著下降(从2.11±0.33降至1.96±0.20,P=0.046)。

要点

  • 动态18F-Flutemetamol PET结合代谢物校正的2室模型可定量心肌淀粉样负荷。
  • 多线性分析1法采用2–20分钟数据生成的VT图像方差最低。
  • 他法米迪治疗6个月后VT显著下降,提示VT对治疗相关变化敏感。

核心结论

  • 动态18F-Flutemetamol PET结合代谢物校正的2组织可逆模型可稳健定量ATTR-CA患者的心肌淀粉样负荷。
  • VT成像对他法米迪治疗6个月后的治疗相关变化具有敏感性。

研究设计与样本

  • 图像衍生输入函数经血-血浆比及代谢物校正,用1组织室模型(0–10分钟)估算心肌血容量分数,用多线性分析1法(2–20分钟)生成VT图像。

主要发现

  • 平均心肌血容量分数为22%±6%。
  • 含代谢物及血浆校正输入函数的2组织可逆模型提供最佳动力学拟合。
  • 采用2–20分钟PET数据的多线性分析1法生成的VT图像方差最低。
  • VT在他法米迪治疗6个月后显著下降(从2.11±0.33降至1.96±0.20,P=0.046)。

关键数值与推荐

  • 平均心肌血容量分数为22%±6%。
  • VT在他法米迪治疗6个月后从2.11±0.33降至1.96±0.20,P=0.046。

临床怎么用

  • 对ATTR-CA患者可采用动态18F-Flutemetamol PET参数化成像定量心肌淀粉样负荷。
  • VT可作为评估他法米迪治疗反应的定量指标,但需结合本研究样本量小的特点谨慎解读。

局限性

  • 动态采集与建模流程较复杂,纳入分析的扫描时间窗有限(0–10分钟与2–20分钟)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In transthyretin cardiac amyloidosis (ATTR-CA), static 18F-flutemetamol PET-derived SUVs do not adequately capture intricate tracer kinetics, limiting the accurate quantification of amyloid burden. We developed dynamic parametric PET imaging methods to improve the quantification of myocardial amyloid burden in ATTR-CA. Methods: Twelve treatment-naïve ATTR-CA patients underwent 60-min dynamic cardiac 18F-flutemetamol PET/CT at baseline and after 6 mo of treatment with tafamidis. Image-derived input functions were corrected for blood-to-plasma ratios and metabolites. Myocardium blood volume fraction was estimated using a 1-tissue compartment model (0-10 min), and volume-of-distribution (V T) images were generated using the multilinear analysis 1 method (2-20 min). V T was correlated with echocardiography, 82Rb myocardial blood flow, and biomarkers. Results: The mean myocardial blood volume fraction was 22% ± 6%. A 2-tissue reversible model with metabolite- and plasma-corrected input functions provided optimal kinetic fits. Multilinear analysis 1 using 2- to 20-min PET data produced V T images with the lowest variance. V T decreased significantly after 6 mo of treatment with tafamidis (from 2.11 ± 0.33 to 1.96 ± 0.20, P = 0.046). Conclusion: Dynamic 18F-flutemetamol PET enabled robust quantification of myocardial amyloid burden using metabolite-corrected 2-compartment modeling. V T imaging demonstrated sensitivity to treatment-related changes in ATTR-CA.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Liu Q, Shi T, Gravel P, et al. Parametric Cardiac Imaging with 18F-Flutemetamol PET to Evaluate the Impact of Tafamidis in Patients with Transthyretin Cardiac Amyloidosis. J Nucl Med. 2026. PMID: 41748295. doi:10.2967/jnumed.125.270003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。